Results 31 to 40 of about 123,893 (301)

Applications of polymer-based nanoparticles in vaccine field

Nanotechnology Reviews, 2019
Polymer-based nanoparticles have good solubility, stability, safety, and sustained release,which increases the absorption of loaded drugs, protects the drugs from degradation, and prolongs their circulation time and targeted delivery.
Guo Sihan, Fu Dongwei, Utupova Assem, Sun Dejun, Zhou Mo, Jin Zheng, Zhao Kai   +6 more
doaj   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

An Update on mRNA-Based Viral Vaccines

Vaccines, 2021
With the success of COVID-19 vaccines, newly created mRNA vaccines against other infectious diseases are beginning to emerge. Here, we review the structural elements required for designing mRNA vaccine constructs for effective in vitro synthetic ...
Subbiah Jeeva, Ki-Hye Kim, Chong Hyun Shin, Bao-Zhong Wang, Sang-Moo Kang   +4 more
doaj   +1 more source

Peptide-based synthetic vaccines

Chemical Science, 2016
This review summarise the current stand and future perspective on synthetic peptide-based vaccines.
Skwarczynski, Mariusz, Toth, Istvan
openaire   +4 more sources

SYNTHETIC BIOLOGY AS AN INSTRUMENT FOR DEVELOPMENT OF INNOVATIVE VACCINES FOR PROPHYLAXIS OF BACTERIAL INFECTIONS

Журнал микробиологии, эпидемиологии и иммунобиологии, 2016
For many decades, live vaccines remain the most effective means for prophylaxis of bacterial infections. Until recently, the main source of vaccine strains were empirically selected bacteria, virulence of which was attenuated due to natural mutations ...
A. V. Kolesnikov, A. V. Kozyr, L. G. Shemyakin, LA. .. Lisitskaya, M. A. Marin, A. K. Ryabko, LA. .. Dyatlov   +6 more
doaj   +1 more source

Dominant Antiviral CD8+ T Cell Responses Empower Prophylactic Antibody-Eliciting Vaccines Against Cytomegalovirus

Frontiers in Immunology, 2022
Human cytomegalovirus (HCMV) is an ubiquitous herpesvirus that can cause serious morbidity and mortality in immunocompromised or immune-immature individuals.
Iris N. Pardieck, Suzanne van Duikeren, Dominique M. B. Veerkamp, Dena J. Brasem, Anke Redeker, Jeroen van Bergen, Wanda Han, Ferry Ossendorp, Gerben Zondag, Ramon Arens   +9 more
doaj   +1 more source

Identification of a protein encoded in the EB-viral open reading frame BMRF2 [PDF]

, 1992
Using monospecific rabbit sera against a peptide derived from a potential antigenic region of the Epstein-Barr viral amino acid sequence encoded in the open reading frame BMRF2 we could identify a protein-complex of 53/55 kDa in chemically induced B95-8,
A. v. Brunn, B Böttinger, E Tschachler, G Myers, GJ Clements, GJ LaRosa, H Takahashi, H Takahashi, H Takahashi, H. Fließbach, H. Wolf, HK Lyerly, HK Lyerly, J Goudsmit, J Goudsmit, JE Gregersen, K Javaherian, K Javaherian, LA Lasky, M Clerici, M Clerici, M. Niedrig, NL Haigwood, P Simmonds, PJ Durda, PW Berman, R Wagner, R. Wagner, RA Neurath, RH Meloen, S Modrow, S Modrow, SD Putney, Susanne Modrow, T Hattori, TJ Palker, Traudel Böltz, Y Devash   +37 more
core   +2 more sources

Approaches to Improve Chemically Defined Synthetic Peptide Vaccines

Frontiers in Immunology, 2018
Progress made in peptide-based vaccinations to induce T-cell-dependent immune responses against cancer has invigorated the search for optimal vaccine modalities.
Brett J. Hos, Elena Tondini, Sander I. van Kasteren, Ferry Ossendorp   +3 more
doaj   +1 more source

Analogue peptides for the immunotherapy of human acute myeloid leukemia [PDF]

, 2015
Accepted manuscript. The final publication is available at: http://link.springer.com/article/10.1007%2Fs00262-015-1762-9The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials.
A Driessche Van, A Gros, A Scardino, A Serrano, A Sevko, A Snyder, A Tsuboi, AB Bakker, Aleksandrs Malinovskis, Andrew Mead, AT Cheuk, AW Purcell, B Engels, B Falini, B Maecker, B Maecker, B Uttenthal, BA Guinn, BA Guinn, Barbara-ann Guinn, C Chaise, C Maccalli, CL Slingluff Jr, D Cilloni, D Mason, DA Gross, DE Speiser, DH Chang, DJ Schwartzentruber, E Estey, E Romano, F Ghiringhelli, FS Hodi, G Khan, H Kobayashi, H Ohminami, HJ Kolb, HJ Stauss, I Bellantuono, J Bae, J Bae, J Fourcade, J Greiner, J Greiner, J Kronke, J Pinilla-Ibarz, J Pinilla-Ibarz, JH Sampson, JJ Molldrem, JL Chen, JL Chen, JN Kochenderfer, JS Ko, JW Wells, K Inoue, K Inoue, K Rezvani, K Rezvani, KM Zirlik, L Chan, L Fong, L Gao, LV Ly, M Harndahl, M Kapp, M Subklewe, MA Cheever, MG Warnock, MM Gubin, MR Parkhurst, MS Bijker, N Hardwick, Nicola R. Hardwick, O Christensen, O Hamid, P Brossart, P Bruggen van der, P Keskinen, PG Maslak, PG Maslak, R Cibotti, RA Padua, RF Schlenk, RJ May, S Frankild, S Hofmann, S Narayan, S Ochsenreither, S Pascolo, S Suekane, S Walter, SH Burg van der, SK Singh, SL Topalian, SP Adams, Susanne Hofmann, T Lovgren, U Keilholz, U Sahin, V Bhardwaj, WS Meng, Y Oka, Z Trajanoski   +102 more
core   +2 more sources

Biochemical prevention and treatment of viral infections – A new paradigm in medicine for infectious diseases [PDF]

, 2004
For two centuries, vaccination has been the dominating approach to develop prophylaxis against viral infections through immunological prevention. However, vaccines are not always possible to make, are ineffective for many viral infections, and also carry
Fang, Fang, Le Calvez, Hervé, Yu, Mang
core   +3 more sources